Cargando…
Reconsidering ‘minimal risk’ to expand the repertoire of trials with waiver of informed consent for research
BACKGROUND: Progress in therapeutic research is slowed by the regulatory burden of clinical trials, which provide the best evidence for guiding treatment. There is a long delay from evidence generation to adoption, highlighting the need for designs that link evidence generation to implementation. OB...
Autores principales: | Monach, Paul A, Branch-Elliman, Westyn |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8442055/ https://www.ncbi.nlm.nih.gov/pubmed/34521663 http://dx.doi.org/10.1136/bmjopen-2020-048534 |
Ejemplares similares
-
Informed consent and research
por: Mandal, Jharna, et al.
Publicado: (2014) -
Informed Consent in Aesthetic Surgery
por: Kapoor, Lalit
Publicado: (2015) -
Informed consent in cluster randomised trials: a guide for the perplexed
por: Nix, Hayden P, et al.
Publicado: (2021) -
Bringing New Meaning to the Term “Adaptive Trial”: Challenges of Conducting Clinical Research During the Coronavirus Disease 2019 Pandemic and Implications for Implementation Science
por: Branch-Elliman, Westyn, et al.
Publicado: (2020) -
Details of risk–benefit communication in informed consent documents
for phase I/II trials
por: Kahrass, Hannes, et al.
Publicado: (2020)